BCYC · Bicycle Therapeutics PLC
$3.90
-0.04 (-1.02%)
At close · Jul 29
Market Cap
$275.06M
Shares
69.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.94
Open$3.98
Day$3.90–3.98
52W$3.87–9.16
Avg vol 30d523K
Short int3.0M · 4.3% float · 7.7d
Short vol37%
Last earningsOct 30, 2025
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−7%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
1%
near low
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−34%
trailing
YTD return
−44%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
13 of 98 funds reported for Jun 30 · net +513.9K sh shares · +2 new
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.27% of float · ▲ +3.4% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+106%
Y/Y
EPS growth
−9%
Y/Y
Free cash flow
$-252.0M
Balance sheet
$597.4M
net cash
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
13 of 98 funds reported for Jun 30 · net +513.9K sh shares · +2 new
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.27% of float · ▲ +3.4% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $4 · 1%
52-wk high $9
vs 200-day avg -31%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCYC
this stock
Bicycle Therapeutics PLC
|
$275.06M | -44.4% | +105.8% | — | 4.3% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +7.3% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCYC | -5.3% | -5.1% | -34.3% | -7.1% | -44.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -4.3% | -5.0% | -41.8% | -6.3% | -53.0% |